Key points from article :
Tome Biosciences specializes in Programmable Genomic Integration, a technology that enables the precise insertion of any genetic sequence of any size into specific locations within the genome. They are at the forefront of genomic medicine, developing cell and gene therapies that offer potential cures for patients by rewriting their genetic code.
Tome Biosciences has emerged from stealth mode with a $213 million investment, aiming to revolutionize genome editing. The company is developing next-generation cell and gene therapies using its advanced Programmable Genomic Integration (PGI) platform, an evolution of the PASTE system. This technology enables the precise insertion of large DNA sequences into specific genomic locations, allowing for extensive genetic modifications that could correct genetic defects and create novel cell therapies.
Co-founded by Omar Abudayyeh and Jonathan Gootenberg, the original developers of PASTE, Tome’s PGI platform represents a major leap in genome editing. "We can create an entire generation of therapies by reprogramming blocks of code in the human genome," said Rahul Kakkar, Tome's CEO. The company is initially focusing on gene therapies for monogenic liver diseases and cell therapies for autoimmune conditions, with plans to expand into other therapeutic areas.
Tome's PGI technology uses proprietary integrases that insert over 30 kilobases of DNA with high precision into both dividing and non-dividing cells, enabling more efficient and targeted treatments. While primarily focused on human therapies, Tome is also exploring applications in research and synthetic biology, highlighting the platform's versatility.
Tome’s rapid growth and ambitious goals reflect their confidence in the PGI platform's ability to redefine genome editing. Kakkar envisions Tome leading a new era in genomic therapies, harnessing this technology to address a wide range of diseases.
